StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Monday morning. The firm issued a hold rating on the stock.

Several other analysts have also recently commented on ONCT. HC Wainwright reduced their target price on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Northland Securities reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, Northland Capmk cut shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $1.11 on Monday. The company has a 50 day simple moving average of $1.69 and a 200 day simple moving average of $5.24. Oncternal Therapeutics has a 1 year low of $1.03 and a 1 year high of $13.14. The firm has a market cap of $3.29 million, a PE ratio of -0.10 and a beta of 1.33.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics at the end of the most recent quarter. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.